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Optimal Management of the Patient with an Episode of
Atrial Fibrillation In and Out of the Hospital:
Acute Cardioversion or Not?
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From the Department of Internal Medicine, Division of Cardiology, University of Michigan Medical Center,
Ann Arbor, Michigan
Learning Objectives:
1) The indications for anticoagulation prior to cardioversion.
2) The advantages of acute cardioversion of atrial fibrillation.
3) The situations in which it is preferable to not acutely cardiovert the patient with atrial
fibrillation.
Introduction
The optimal management of a patient with
new-onset atrial fibrillation (AF) is highly indi-
vidualized. Frequently, the key management de-
cision is whether or not to perform acute cardio-
version. This decision involves asking two
questions: (1) should cardioversion be performed
at all? And, if so, (2) should cardioversion be
performed acutely or should it be delayed?
To answer the first question, the benefits of
sinus rhythm, the risks of cardioversion, and the
likelihood of recurrence must be considered. The
answer to the second question depends largely on
the duration of AF. In patients who have had AF
for < 48 hours, there is little reason to delay
cardioversion unless there is a reversible trigger
that may result in an early recurrence, or unless
there is a high likelihood of spontaneous conver-
sion. In patients who have had AF for > 48
hours, or in whom the duration is unclear, an
atrial thrombus must be excluded by a trans-
esophageal echocardiogram (TEE) if acute car-
dioversion is being considered, unless the situa-
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tion is emergent. An alternative approach is to
delay cardioversion until the patient has been
anticoagulated for 3 weeks. This avoids the need
for a TEE and avoids hospitalization to initiate
heparin, but prolongs the duration of symptoms
and may diminish the probability of restoring
sinus rhythm by allowing time for more atrial
remodeling to occur. Indeed, the various strate-
gies for managing an episode of AF are each
associated with their own advantages and disad-
vantages. In this monograph, the issues sur-
rounding the most appropriate management of an
episode of AF will be reviewed.
Should Cardioversion be Performed?
Initial Evaluation
The initial evaluation of a patient with AF
includes confirmation of the rhythm diagnosis,
exclusion of Wolff-Parkinson-White syndrome,
determination of symptom severity, evaluation
for underlying heart disease, and identification of
the cause. The accurate diagnosis of AF is im-
portant but is not always achieved. A recent
survey of cardiologists and cardiology fellows
found that 74% misdiagnosed an ECG of AF
with prominent atrial activity (> 0.2 mV) in
more than one lead, as atrial fiutter (unpublished
data). A study of internal medicine house officers
found that 31% of those surveyed misdiagnosed
rapid AF as paroxysmal supraventricular tachy-
cardia.' The same study found that 32% of the
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arrbytbmias treated witb adenosine at a univer-
sity medical center were AFs. Altbougb tbe ir-
regularity of tbe ventricular response may be less
apparent wben tbe ventricular response is rapid,
tbe ballmarks of AF can usually be identified.
Tbe Wolff-Parkinson-Wbite syndrome must
be diagnosed early so tbat tbe use of AV nodal
blocking agents, wbicb migbt accelerate acces-
sory patbway conduction, can be avoided.^ Fur-
tbermore, early diagnosis is important because
successful ablation of tbe accessory patbway
may prevent recurrent episodes of AF.̂ "*
Patients witb AF associated witb severe symp-
toms, sucb as significant angina or bemodynamic
instability, sbould undergo immediate electrical
cardioversion. Tbis is in accordance witb Ad-
vanced Cardiac Life Support guidelines.^ For
patients witb moderate symptoms, ventricular
rate control can significantly improve symptoms
and allow time to stabilize tbe patient wbile
cardioversion is being considered.
Identification of cardiac patbology sucb as
pericarditis, acute myocardial infarction, mitral
stenosis, or bypertropbic cardiomyopatby will
bave an impact on botb acute and long-term
management of a patient witb AF. Tberefore, a
careful bistory must be taken and a pbysical
examination witb focused cardiac testing, wbicb
sbould include a transtboracic ecbocardiogram,
sbould be performed in patients wbo present witb
AF. Tbe initial evaluation sbould also include
identification of major reversible triggers before
proceeding witb cardioversion. Attempts sbould
be made to reverse triggers, sucb as severe byp-
oxemia, tbat migbt lead to an early recurrence of
AF. For example, a patient witb severe respira-
tory distress may need ventilatory support and
correction of bypoxemia before cardioversion is
attempted.
Benefits of Sinus Rhythm
Tbere are many tbeoretical advantages to si-
nus rbytbm. Tbe most obvious benefit of sinus
rbytbm is tbe bemodynamic advantage tbat oc-
curs witb restoration of atrial mecbanical func-
tion and AV syncbrony. Altbougb it is difficult to
predict wbicb patients are likely to feel better
after cardioversion, patients witb diastolic dys-
function, commonly seen in tbe elderly and tbose
witb bypertension, are dependent upon atrial
contraction. It is commonly believed tbat patients
witb congestive beart failure are more likely to
benefit from a return of atrial function. However,
patients witb advanced beart failure develop a
restrictive ventricular filling pattern sucb tbat tbe
atrial contribution to filling is minimal.^ Resto-
ration of sinus rbytbm may not improve cardiac
output. Tbis concept is supported by a study'' tbat
found no improvement after 6 weeks in exercise
peak VO2, cardiac dimensions, or neurobumoral
status among patients witb mild to moderate
beart failure wbo underwent cardioversion for
AF.
A second benefit of cardioversion is control of
tbe ventricular rate. Tbere is a significant risk of
tacbycardia-induced cardiomyopatby among pa-
tients witb AF wbose ventricular response cannot
be controlled.* In fact, some patients tbougbt to
bave idiopatbic dilated cardiomyopatby and AF
may bave first developed rapid AF tbat subse-
quently led to a cardiomyopatby.^ Any metbod to
decrease tbe rate can improve ventricular func-
tion, including drugs, cardioversion,"' AV junc-
tion ablation," or modification.'^ Tberefore, pa-
tients witb refractory rapid ventricular rates
sbould be strongly considered for cardioversion,
regardless of tbe presence or absence of symp-
toms.
A tbird benefit of cardioversion is regulariza-
tion of tbe ventricular rbytbm. Even wben tbe
ventricular rate is well controlled, cardiac output
is lower wben tbe ventricular rbytbm is irregular
tban wben it is regular.'^ Tbis may explain wby
patients witb congestive beart failure may be
more likely to benefit from AV junction ablation
and pacing compared witb AV node modifica-
tion, despite tbe adverse bemodynamics caused
by rigbt ventricular apical pacing."*
A fourtb benefit is tbe potential for reducing
tbe risk of tbromboembolic complications. Tbere
are no data tbat demonstrate a reduction in stroke
risk following maintenance of sinus rbytbm, but
it appears tbat tbe development of left atrial
tbrombi is associated witb left atrial enlargement
and reduced atrial mecbanical function. Studies
bave demonstrated an eventual improvement in
left atrial mecbanical function following cardio-
version'^ and bave indicated tbat tbe mainte-
nance of sinus rbytbm may prevent atrial en-
largement. "̂  Tberefore, it is plausible tbat in
patients witb risk factors for stroke during AF,
restoration of sinus rbytbm reduces tbe risk of
stroke over tbe long term. On tbe otber band, tbe
causes of stroke in patients witb AF are multi-
factorial, and some factors, sucb as complex aor-
tic plaques, may be responsible for an ongoing
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risk of stroke despite the restoration of sinus
rhythm.
starting therapy with an additional drug to main-
tain sinus rhythm.
Likelihood of Successful Conversion and
Recurrence
The likelihood of successful conversion and
the likelihood of recurrent AF should be consid-
ered before an attempt at cardioversion. Most
patients can be successfully converted to sinus
rhythm. The primary predictors of failure to con-
vert with external cardioversion are body mass
and the duration of AF. A study of 80 patients
who underwent external cardioversion found that
gender, left atrial enlargement, electrode pad po-
sition, etiology of AF, presence of left ventricu-
lar failure, and prior treatment with verapamil or
beta blockers did not predict cardioversion suc-
cess.'"' For patients who fail pharmacologic and
external cardioversion, internal cardioversion is
an option."^ Therefore, patients should not be
considered ineligible for cardioversion merely
because the likelihood of initial failure is per-
ceived to be high. The use of certain terminology
in reference to AF such as "chronic" in the med-
ical literature and in patients' records has com-
pounded the problem of patients not being given
the option of cardioversions. Patients who carry a
diagnosis of "chronic" AF may have a long his-
tory of self-terminating episodes of AF (parox-
ysmal) or have non-self-terminating AF, and
have either failed cardioversion (permanent AF)
or have never had an attempt at cardioversion
(persistent AF).'^
Although many factors have been associated
with recurrence of AF following successful car-
dioversion, such as left atrial size, presence of
heart disease, age, and duration of AF,̂ ^ the
predictive value of each factor is not strong in
every study. For example, left atrial size and
duration of AF may not predict recurrence after
cardioversion among patients treated with anti-
arrhythmic drugs.2' Therefore, at least one at-
tempt at cardioversion often is appropriate before
deciding that a patient should be left in AF. In
some cases, however, even one attempt at car-
dioversion may not be worthwhile. For example,
a 75-year-old man with a mechanical aortic valve
who is found to be in AF with a controlled
ventricular response, who has no symptoms at-
tributable to the AF, and who has tolerated war-
farin for several years may prefer to remain in
AF instead of undergoing cardioversion and/or
Should Cardioversion be Performed Acutely
or Postponed?
Once it has been decided to perform cardio-
version, it must be decided whether cardiover-
sion should be performed acutely or should be
delayed. This decision is based on many factors,
but hinges upon the duration of AF.
The decrease in left atrial transport and stasis
of blood that occurs with AF results in intravas-
cular thrombogenesis, platelet activation, and
thromboembolism.22-24 in addition, the immedi-
ate postcardioversion period is associated with
left atrial mechanical dysfunction that persists
for a time proportional to the duration of AF,'-*̂
appears to be calcium mediated,2'' and further
increases the risk of stroke. It is unclear how
much time following the onset of AF must elapse
before cardioversion might result in thromboem-
bolism. A time of 48 hours is frequently used as
a cutoff point,25 because it has been shown that
cardioversion in patients with AF for < 48 hours
can be performed relatively safely without anti-
coagulation. One study^"' followed 375 patients
who presented with AF thought to be of < 48
hours in duration and who either spontaneously
converted or underwent cardioversion without
heparin or warfarin. One patient had a stroke,
one patient had a transient ischemic attack, and
one patient had a peripheral embolism, indicating
an overall thromboembolic risk of < 1%. How-
ever, some physicians advocate anticoagulation
prior to cardioversion for all patients, regardless
of the duration of AF, because clot formation
may occur sooner than 48 hours and because
estimates of the duration of a particular episode
of AF may be inaccurate.
There is often uncertainty regarding the time
of onset of an episode of AF. Patients with par-
oxysmal AF have been shown to have more
sustained asymptomatic episodes than symptom-
atic episodes.2^^ Therefore, it is possible that
some patients who present with AF have been
fibrillating for several days before the onset of
symptoms.
Because some patients with AF present with
insidious symptoms of weakness or dyspnea, it is
usually recommended that only patients who
have had AF of < 48 hours in duration and who
can pinpoint the time of onset with confidence
should undergo cardioversion without anticoag-
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ulation. The remaining patients should undergo
cardioversion only after measures have been
taken to reduce the risk of stroke.
AF < 48 Hours in Duration
Acute cardioversion leads to prompt resolu-
tion of symptoms, avoids the need for anticoag-
ulation, and prevents further electrical and me-
chanical remodeling in the atria. Therefore, there
is little reason to delay cardioversion in patients
who present with AF < 48 hours in duration.
However, there are two situations in which a
delay may be advantageous.
The first situation is when there is a high
likelihood of spontaneous conversion. On aver-
age, the incidence of spontaneous cardioversion
of new-onset AF is approximately 50%. A recent
study of 356 patients with AF of < 72 hours in
duration found an incidence of spontaneous con-
version of 68%.28 The only predictor of sponta-
neous conversion was presentation within 24
hours. Therefore, an example of a patient who
may benefit from a delay in cardioversion is a
young, otherwise healthy individual who devel-
ops AF after excessive alcohol consumption and
who presents to the hospital within a few hours
after the onset of symptoms. Another example is
a patient who develops AF during a procedure
such as cardiac catheterization or a dobutamine
stress echocardiogram.
On the other hand, a patient in whom there is
a contraindication to anticoagulation should un-
dergo prompt cardioversion, despite a high like-
lihood of spontaneous conversion. For example,
a patient who presents with gastrointestinal
bleeding and AF of < 48 hours in duration
should be cardioverted promptly, because if
spontaneous conversion does not occur within 48
hours, the window of opportunity for a low like-
lihood of stroke will have been lost.
The second situation in which cardioversion
should be postponed is when there is a persistent
reversible trigger, which will probably result in
an early recurrence if left uncorrected. An exam-
ple is a patient with AF in the setting of thyro-
toxicosis, in whom cardioversion should be de-
ferred until the thyroid disease has been treated.
AF > 48 Hours in Duration
Patients with AF > 48 hours in duration
should undergo steps to reduce the risk of em-
bolism with cardioversion, regardless of the ab-
sence of traditional risk factors that have been
associated with stroke during chronic AF. There
are two general approaches to reduce the risk of
thromboembolism. The first approach is antico-
agulation with warfarin for 3 weeks prior to
cardioversion. An alternative strategy is to per-
form a TEE and perform cardioversion after in-
travenous heparin is started if no thrombus is
found.29 Anticoagulation for at least 4 weeks
after conversion to sinus rhythm must be admin-
istered regardless of which approach is chosen.
Both approaches are acceptable and are recom-
mended by recently published ACC/AHA guide-
lines.3o The decision of which approach to follow
depends on several factors.
There are advantages and disadvantages of
early cardioversion using a TEE-guided ap-
proach for patients with AF > 48 hours in dura-
tion. One advantage is that symptomatic patients
will benefit from the prompt resolution of symp-
toms. Another advantage is the avoidance of the
risk and inconvenience associated with anticoag-
ulation for 3 weeks prior to cardioversion. Al-
though the bleeding risk during this 3-week pe-
riod may be low, the precardioversion period of
anticoagulation is often > 3 weeks because of
the time required to achieve therapeutic antico-
agulation with warfarin in some patients. There-
fore, early cardioversion may avoid several
weeks of delay.
A theoretical advantage of early cardioversion
is a lower incidence of recurrence. It has been
shown that an episode of AF results in shortening
of atrial refractoriness (electrical remodeling)
that promotes a recurrent episode of AF,^'-'^ arid
repeated cardioversions may be associated with
progressively longer arrhythmia-free intervals.
Therefore, early cardioversion allows less time
for electrical remodeling to occur and may be
more likely to be followed by sustained sinus
rhythm.
A disadvantage of the TEE-guided approach is
the need for the patient to undergo a TEE. How-
ever, this is a safe procedure and often provides
other valuable information. Therefore, for pa-
tients who are already in the hospital, there is
little disadvantage to early cardioversion. The
TEE-guided approach has been shown to be cost-
effective for inpatients.33 However, the early ap-
proach to cardioversion requires hospitalization
to initiate heparin while starting warfarin. There-
fore, a patient with AF who is minimally symp-
tomatic and who has likely been in AF chroni-
cally would obtain little benefit from early
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cardioversion. An approach using a TEE-guided
cardioversion followed by outpatient subcutane-
ous low-molecular weight heparin offers the ad-
vantages of early cardioversion and the benefit of
avoiding hospitalization. This strategy awaits
further study.
The other disadvantage of the TEE-guided
approach is the dilemma created when a patient
is found to have an atrial thrombus. It is clear that
patients with a thrombus who have not been
anticoagulated should not undergo cardioversion
acutely, if possible. However, it is not clear
when, if ever, cardioversion can be safely per-
formed. It is possible that cardioversion could be
safely performed following 3 weeks of anticoag-
ulation, even if the atrial thrombus is still
present. However, some investigators recom-
mend a repeat TEE and more aggressive antico-
agulation prior to cardioversion if a clot is still
present. Aggressive steps to minimize an em-
bolic stroke must be weighed against the risks of
delaying cardioversion, the risks of hemorrhagic
complications, and how likely the patient is to
benefit from sinus rhythm.
AF Following Cardiac Surgery
Postoperative AF deserves special mention.
AE is a common problem after open heart sur-
gery and has unique features. AF occurs in pa-
tients who are in the hospital and monitored, is
secondary to triggers that often resolve over
time, may occur in patients who have a contra-
indication to anticoagulation, and often prolongs
the hospital length of stay. AF following noncar-
diac surgery is less common, with an incidence
of approximately 6%, but shares many of these
features. 3"*
Although there are effective prophylactic reg-
imens for postoperative AF, such as beta block-
ers,35 sotalol,3<' and orally administered amioda-
rone,3^ AF continues to be a significant problem.
Much of the pathology contributing to the initi-
ation and perpetuation of AF following cardiac
surgery, such as pericarditis and elevated cat-
echolamines, resolves spontaneously over time.
Therefore, a successful cardioversion may be
followed by an early recurrence, and a delay in
cardioversion may be followed by spontaneous
conversion. In a study using temporary epicardial
wires placed at the time of cardiac surgery for
atrial defibrillation, the incidence of early recur-
rence (< 60 sec after defibrillation) following
successful conversion of postoperative AF was
The decision of whether to perform cardiover-
sion acutely depends on the anticipated length of
stay and often is governed by logistical factors.
For example, if a patient develops AF on the day
of anticipated discharge and ventricular rate con-
trol is achieved within a short period of time, it
may be preferable to initiate therapy with warfa-
rin, continue drugs to control the rate, and dis-
charge the patient when the cardioversion pro-
cess is expected to prolong the hospital stay. In a
recent study,^^ 12 patients with postoperative AF
who were discharged from the hospital with war-
farin and drugs for rate control but without any
attempts at cardioversion were compared with 67
patients discharged after cardioversion. Patients
discharged in AF had a shorter length of stay and
lower hospital costs compared with patients dis-
charged in sinus rhythm. However, if the re-
sources to promptly perform cardioversion are
available, the patient can be discharged on the
same day and avoid the need for anticoagulation.
Cardioversion Technique and Risks
Cardioversion of AF can be achieved either
pharmacologically or electrically. Pharmacologic
cardioversion is associated with proarrhythmia,
including sustained polymorphic ventricular
tachycardia with drugs that prolong repolariza-
tion such as sotalol, incessant monomorphic ven-
tricular tachycardia as seen with flecainide, and
bradycardia. It remains controversial which out-
patients should be hospitalized prior to initiation
of oral antiarrhythmic therapy. It is likely that
patients without structural heart disease can be
safely treated as outpatients. However, a recent
retrospective study found clinically significant
complications during in-hospital monitoring in 1
of 5 patients started on sotalol, and absence of
heart disease failed to distinguish a low-risk
group.'*" Although not approved for use in the
United States for AF, amiodarone appears to be
safe when started in low doses and can be started
on an outpatient basis even in the presence of
heart disease.
For patients who are already hospitalized and
monitored, intravenous options include procain-
amide, ibutilide, and amiodarone. Digoxin has no
role in the conversion of AF. The Digitalis in
Acute AF (DAAF) Trial included 239 patients
and found that 51% of patients who received
digoxin converted to sinus rhythm after 16 hours.
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compared with 46% of patients who received
placebo.'" Ibutilide has recently been compared
with procainamide and was found to have a
higher cardioversion success rate than procain-
amide (51% vs 21%, P = 0.005).'*? The risk of
sustained polymorphic ventricular tachycardia is
approximately 2%, and appears to occur more
commonly in women and in patients with con-
gestive heart failure. An additional advantage of
ibutilide is that when conversion is not initially
achieved, the energy required to cardiovert may
be lowered by ibutilide (unpublished data). Al-
though initial trials suggested that amiodarone
was effective in cardioversion, a randomized pla-
cebo-controlled trial of 100 patients found no
benefit.'*^
Electrical cardioversion is safe and highly ef-
fective.'*'* No antiarrhythmic drug therapy has a
higher success rate. Electrical cardioversion was
initially shown to be associated with more sig-
nificant atrial "stunning" compared with pharma-
cologic cardioversion in nonrandomized trials.'*^
Therefore, it was felt that pharmacologic cardio-
version might be associated with a lower risk of
embolism. However, more recent studies'**" have
found no difference in the effect on atrial func-
tion between electric and pharmacologic cardio-
version. Complications associated with electrical
cardioversion, including ventricular fibrillation
and postconversion bradycardia, are rare. In fact,
in a prospective study of 1,152 patients who
underwent either pharmacologic or electrical car-
dioversion, only five patients died, all of whom
were related to quinidine therapy for pharmaco-
logic cardioversion.'*' Therefore, if the facilities
are readily available, there is little reason to
delay electrical cardioversion while treatment
with antiarrhythmic drugs is instituted.
When there is a high likelihood of recurrence,
it may be of value to have therapeutic plasma
drug levels present at the time of cardioversion to
avoid an early recurrence of AF. Therefore, in
this case, it may be useful to delay electrical
cardioversion. On the other hand, prophylactic
drug therapy can usually be initiated after car-
dioversion, and in some patients can be avoided
altogether. For example, it would be acceptable
to use no antiarrhythmic drugs following cardio-
version of a patient who presents with his or her
first episode of AF.
Given the inefficiency of transthoracic energy
delivery, high energies are required for success-
ful external cardioversion. Therefore, sedation is
required when the procedure is performed elec-
tively. Several anesthetics have been shown to be
useful in this setting, including intravenous mi-
dazolam, propofol, and etomidate.'**"5o Electro-
physiologists who are experienced with con-
scious sedation can safely administer sedation
for the delivery of painful shocks.^' However,
because some agents such as propofol are asso-
ciated with a high incidence of apnea,'* '̂ their use
is often restricted by hospitals to anesthesiolo-
gists. Low-energy transvenous cardioversion us-
ing specially designed catheters is an option for
patients who cannot receive sedation.52,53 xhis
concept has recently been expanded to the post-
operative setting. Liebold et al.̂ ^ were able to
successfully initially convert 80% of patients
who developed AF after cardiac surgery with a
mean energy of 5 J delivered through temporary
epicardial wires that were placed intraopera-
tively. Only 30% of the patients required seda-
tion.
Conclusion
There is increasing evidence to support acute
cardioversion in patients with AF. Acute cardio-
version results in prompt resolution of symp-
toms, reduces the time allowed for electrical
remodeling to occur, reduces the duration of
postcardioversion atrial mechanical dysfunction,
and avoids the need for anticoagulation when
performed within 48 hours of onset of AF. When
acute cardioversion is being considered in a sta-
ble patient with AF > 48 hours, a TEE should be
performed to exclude an atrial thrombus prior to
cardioversion, and 4 weeks of warfarin therapy
should be continued after cardioversion.
The management of AF must be individual-
ized and must consider the duration of AF, the
perceived benefit of sinus rhythm, the likelihood
of a spontaneous conversion, the presence of
ongoing triggers, the need for hospital admis-
sion, and logistical factors. Although clinical
judgment will always play an important role in
determining the optimal treatment strategy in
individual patients, additional prospective stud-
ies are needed to clarify unsettled issues related
to AF. For example, it is unclear whether acute
cardioversion or rate control/anticoagulation is
the safer and least costly strategy in patients with
postoperative AF. In addition, the role of newer
agents for anticoagulation such as subcutaneous
low-molecular weight heparin, and the role of
newer techniques that permit low-energy cardio-
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version without sedation remain to be deter-
mined.
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